Published in Nat Commun on August 17, 2016
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell (2017) 0.75
Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles. Front Immunol (2017) 0.75
Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Semin Immunol (2017) 0.75
Mn(2+)-coordinated PDA@DOX/PLGA nanoparticles as a smart theranostic agent for synergistic chemo-photothermal tumor therapy. Int J Nanomedicine (2017) 0.75
Nanoscale metal-organic frameworks coated with poly(vinyl alcohol) for ratiometric peroxynitrite sensing through FRET. Chem Sci (2017) 0.75
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat Commun (2017) 0.75
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Immunity, inflammation, and cancer. Cell (2010) 28.27
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Cancer immunotherapy comes of age. Nature (2011) 12.35
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Photodynamic therapy of cancer: an update. CA Cancer J Clin (2011) 6.08
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
The future of immune checkpoint therapy. Science (2015) 5.59
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res (2011) 5.30
The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97
Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer (2006) 3.93
Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater (2011) 3.40
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 3.02
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64
Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev (2010) 2.44
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med (2015) 1.98
PD-1 as a potential target in cancer therapy. Cancer Med (2013) 1.98
Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett (2013) 1.54
Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol (2011) 1.50
Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res (2007) 1.37
Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. Br J Cancer (1995) 1.29
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther (2013) 1.22
Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis (2010) 1.22
Porphyrin-phospholipid liposomes permeabilized by near-infrared light. Nat Commun (2014) 1.20
Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res (1999) 1.19
Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant (2011) 1.19
Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev Clin Immunol (2011) 1.11
Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. Nat Commun (2014) 1.11
Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem Rev (2015) 1.10
Enzymatic regioselection for the synthesis and biodegradation of porphysome nanovesicles. Angew Chem Int Ed Engl (2012) 1.06
Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med (2014) 1.03
Metastatic colorectal cancer. Curr Treat Options Oncol (2001) 1.00
Self-assembled core-shell nanoparticles for combined chemotherapy and photodynamic therapy of resistant head and neck cancers. ACS Nano (2015) 0.93
Targeting-triggered porphysome nanostructure disruption for activatable photodynamic therapy. Adv Healthc Mater (2014) 0.92
Role of the immune system in mediating the antitumor effect of benzophenothiazine photodynamic therapy. Photochem Photobiol (1999) 0.90
Nanomedicine Applications of Hybrid Nanomaterials Built from Metal-Ligand Coordination Bonds: Nanoscale Metal-Organic Frameworks and Nanoscale Coordination Polymers. Chem Rev (2015) 0.90
Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer. Nat Rev Clin Oncol (2014) 0.87
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther (2014) 0.85
Targeting Programmed Cell Death 1 in Ovarian Cancer. J Clin Oncol (2015) 0.84
Tumor immune microenvironment characterization and response to anti-PD-1 therapy. Cancer Biol Med (2015) 0.80
Chemoselective single-site Earth-abundant metal catalysts at metal-organic framework nodes. Nat Commun (2016) 0.75